Pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention strategy. Per the CDC in 2019, there were 35,000 new HIV infections in the United States and cisgender women accounted for almost 20% of new HIV diagnoses. However, they still remain underrepresented among PrEP users, comprising only 9% of PrEP users in 2024. Recent advances have expanded PrEP options, including long-acting injectable PrEP (LAI PrEP), providing an alternative to daily oral therapy. Midway Specialty Care Center (Midway), a specialty multiclinic infectious disease organization in Florida, provides comprehensive sexual health and infectious disease services to medically underserved populations and has the established infrastructure to provide screening for sexually transmitted infections (STI) and PrEP delivery.

Operating in the southern United States—a region accounting for 52% of new HIV diagnoses but only 38% of PrEP users—Midway has strategically located clinics in areas of greatest need². This geographic and demographic disparity underscores the importance of targeted strategies to increase PrEP awareness, access, and utilization among cisgender women.

In this presentation, we share results of our outreach efforts to engage cisgender women for HIV prevention services, including PrEP.